Brokers Set Expectations for ACRV FY2024 Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for shares of Acrivon Therapeutics in a research report issued on Monday, February 3rd. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($2.42) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Acrivon Therapeutics' current full-year earnings is ($2.49) per share. Cantor Fitzgerald also issued estimates for Acrivon Therapeutics' FY2025 earnings at ($2.55) EPS.

A number of other brokerages also recently issued reports on ACRV. KeyCorp began coverage on shares of Acrivon Therapeutics in a report on Friday, January 31st. They set an "overweight" rating on the stock. BMO Capital Markets dropped their price target on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an "outperform" rating on the stock in a report on Thursday, November 14th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $22.00 price target on shares of Acrivon Therapeutics in a report on Thursday, November 14th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $23.67.

Acrivon Therapeutics Price Performance

ACRV stock traded down $0.49 during trading on Wednesday, hitting $6.02. 31,865 shares of the stock traded hands, compared to its average volume of 68,657. The firm's 50 day moving average is $6.22 and its two-hundred day moving average is $7.29. The stock has a market cap of $187.46 million, a price-to-earnings ratio of -2.23 and a beta of 0.77. Acrivon Therapeutics has a 1 year low of $3.19 and a 1 year high of $11.90.

Hedge Funds Weigh In On Acrivon Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ACRV. China Universal Asset Management Co. Ltd. bought a new stake in Acrivon Therapeutics during the 4th quarter worth approximately $40,000. Dimensional Fund Advisors LP bought a new stake in Acrivon Therapeutics during the 2nd quarter worth approximately $58,000. Barclays PLC raised its stake in Acrivon Therapeutics by 51.2% during the 3rd quarter. Barclays PLC now owns 33,306 shares of the company's stock worth $233,000 after acquiring an additional 11,273 shares during the period. JPMorgan Chase & Co. raised its stake in Acrivon Therapeutics by 548.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company's stock worth $238,000 after acquiring an additional 28,748 shares during the period. Finally, Exome Asset Management LLC bought a new stake in Acrivon Therapeutics during the 3rd quarter worth approximately $817,000. Hedge funds and other institutional investors own 71.62% of the company's stock.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.